LEADING-EDGE TECHNOLOGIES

With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell.

The CAP® Technology comprises a portfolio of proprietary cell lines and platform technologies based on the CAP® cells, a superior production cell line for complex biopharmaceuticals, including viral vectors, exosomes and complex proteins.

CEVEC’s CAP® Ad Platform is based on the CAP® cell line and is the ideal production platform for RCA-free Adenoviral vectors for gene therapy and vector vaccine applications.

With the CAP® Go Platform CEVEC provides a solution to the increasing need for production of complex and highly glycosylated recombinant proteins, including laminins, coagulation factors and plasma proteins.

STABLE AAV PRODUCER CELL LINES

With the ELEVECTA® Technology CEVEC has developed the only genuine AAV Producer Cell Line. All components necessary for AAV production are stably integrated into the producer cell.

ADENOVIRAL VECTORS AND VACCINES

CEVEC’s CAP® Ad Technology is the ideal production platform for RCA-free Adenoviral vectors. The platform is based on CAP® cells, one of the best documented and most thoroughly tested human suspension cell lines available.

GLYCO-OPTIMIZED PROTEINS

With CAP®Go CEVEC provides a solution to enable recombinant production of complex and highly glycosylated proteins, including Laminins, Blood Coagulation Factors and other Plasma Proteins. A wide range of specifically engineered cell lines is available.

© CEVEC Pharmaceuticals GmbH 2021